I
Interline Therapeutics
Leveraging advances in genomics, proteomics, and computational chemistry to identify new medicines
About Interline Therapeutics
Interline Therapeutics is a biotech startup operating in the drug discovery market. The company's primary focus is on understanding protein communities and their role in disease progression. Using their proprietary discovery platform, Interline identifies new medicines that target genetically validated signaling pathways. These pathways are crucial in the development and progression of diseases, and by targeting them, Interline aims to correct dysfunctional disease networks.
Read full description
Interline's business model is centered around the development and commercialization of these new medicines. The company's potential clients include healthcare providers, hospitals, and patients suffering from diseases that can be treated by their drug candidates. Interline's revenue is likely generated through the sale of their medicines, as well as potential partnerships or licensing agreements with larger pharmaceutical companies.
The company places a strong emphasis on deep science and rapid innovation, with a culture that prioritizes both patients and employees. They are committed to creating a diverse and inclusive team, united by common values. This approach not only fosters a positive working environment but also ensures a wide range of perspectives in their research and development efforts.
In summary, Interline Therapeutics is a promising startup in the biotech industry, leveraging a unique approach to drug discovery to potentially revolutionize treatments for various diseases.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Brisbane, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2021 | $60M | $238M | Foresite Capital · ARCH Venture Partners | — |
| SEEDOther financing | Mar 2021 | $33M | $130M | Foresite Capital · ARCH Venture Partners | — |
Growth signals
Latest recorded traffic for Interline Therapeutics is 110 monthly website visits, down 95.9% over the last three months. Interline Therapeutics's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Interline Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Interline Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.